• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session

    12/13/22 12:14:33 PM ET
    $ACMR
    $AMAM
    $ANGI
    $APVO
    Industrial Machinery/Components
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACMR alert in real time by email

    Gainers

    • OpGen, Inc. (NASDAQ:OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
    • Netcapital Inc. (NASDAQ:NCPL) shares jumped 100% to $2.77 following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
    • Onion Global Limited (NYSE:OG) gained 65% to $0.33.
    • Jiuzi Holdings, Inc. (NASDAQ:JZXN) shares jumped 46.7% to $0.2171.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) rose 33.3% to $0.6119 after surging over 55% on Monday. Faraday Future Intelligent Electric recently appointed FF China CEO Xuefeng (XF) Chen as Global CEO of the company
    • BeyondSpring Inc. (NASDAQ:BYSI) jumped 31% to $0.9995 after the company presented data with plinabulin for the prevention of docetaxel-induced neutropenia in patients with non-small cell lung cancer and breast cancer at three medical conferences.
    • Fluence Energy, Inc. (NASDAQ:FLNC) shares gained 28% to $22.05 after the company reported better-than-expected Q4 sales.
    • Shineco, Inc. (NASDAQ:SISI) jumped 27% to $1.6518 after the company announced its subsidary was granted a USPTO patent and FDA marketing approval for its in-situ fecal specimen sampling device.
    • Gritstone bio, Inc. (NASDAQ:GRTS) gained 27% to $3.2807. Gritstone bio was granted two new US patents for self-amplifying mRNA.
    • Prenetics Global Limited (NASDAQ:PRE) rose 27% to $2.35. Prenetics recently announced a $20 million buyback.
    • SenesTech, Inc. (NASDAQ:SNES) gained 26% to $3.13.
    • Magenta Therapeutics, Inc. (NASDAQ:MGTA) gained 25.2% to $1.44 after the company highlighted updated data from the ongoing MGTA-117 Phase 1/2 dose-escalation trial at the American Society of Hematology 2022 Annual (ASH) Meeting.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) rose 24.8% to $1.65.
    • ClearSign Technologies Corporation (NASDAQ:CLIR) jumped 24.8% to $0.69.
    • Moderna, Inc. (NASDAQ:MRNA) surged 22.8% to $202.86 after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.
    • Schrödinger, Inc. (NASDAQ:SDGR) rose 22.6% to $20.88.
    • Dada Nexus Limited (NASDAQ:DADA) gained 21.7% to $8.02. Shares of Chinese companies traded higher following the recent easing of Covid restrictions in China, which has helped increase travel activity.
    • MamaMancini's Holdings, Inc. (NASDAQ:MMMB) rose 21.4% to $1.5308 following better-than-expected Q3 results.
    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) rose 21.4% to $34.70 after gaining over 5% on Monday.
    • Rallybio Corporation (NASDAQ:RLYB) shares climbed 19.8% to $10.43. JP Morgan, last week, initiated coverage on Rallybio with an Overweight rating and announced a price target of $21.
    • ACM Research, Inc. (NASDAQ:ACMR) gained 19.6% to $10.43.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) gained 19.4% to $4.3115. Wave Life Sciences and GSK plc have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program targeting alpha-1 antitrypsin deficiency, WVE-006.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) rose 19.1% to $0.8799.
    • Entrada Therapeutics, Inc. (NASDAQ:TRDA) jumped 18% to $19.16. Vertex Pharmaceuticals and Entrada Therapeutics recently announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1).
    • Summit Therapeutics Inc. (NASDAQ:SMMT) gained 16.6% to $3.29.
    • 180 Life Sciences Corp. (NASDAQ:ATNF) rose 15.5% to $0.3101.
    • National Western Life Group, Inc. (NASDAQ:NWLI) gained 14.8% to $277.01.
    • 2U, Inc. (NASDAQ:TWOU) gained 14.1% to $7.95.
    • Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) jumped 13.1% to $11.38.
    • Ribbon Communications Inc. (NASDAQ:RBBN) surged 12.5% to $2.98.
    • Gaotu Techedu Inc. (NASDAQ:GOTU) gained 12% to $1.87. Gaotu Techedu, last month, reported a third-quarter FY22 sales decline of 45.6% year-on-year to RMB606.2 million ($85.21 million).
    • Mullen Automotive, Inc. (NASDAQ:MULN) jumped 11.5% to $0.2152 after the company announced it signed its first U.S. dealer partner.
    • Pinterest, Inc. (NYSE:PINS) climbed 10.6% to $26.12. Piper Sandler upgraded Pinterest from Neutral to Overweight and raised the price target from $25 to $30.
    • ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) gained 10.1% to $7.84 after SVB Leerink initiated coverage on the stock with an Outperform rating and a $14 price target.
    • Angi Inc. (NASDAQ:ANGI) gained 9.7% to $2.3250 after Citigroup initiated coverage on the stock with a Buy rating and a $2.60 price target.
    • Pardes Biosciences, Inc. (NASDAQ:PRDS) rose 9.6% to $1.26. JMP Securities initiated coverage on Pardes Biosciences with a Market Outperform rating and announced a price target of $9.
    • MediaCo Holding Inc (NASDAQ:MDIA) rose 5.3% to $1.1485 after the company said it has divested the assets of Fairway Outdoor LLC to Lamar Advertising Company for $78.6 million.
    • Oracle Corporation (NYSE:ORCL) gained 3% to $83.69 after the company reported better-than-expected results for its second quarter on Monday.


    Losers

    • Quotient Limited (NASDAQ:QTNT) fell 46% to $0.37. Quotient announced intent to voluntary delist from the Nasdaq Global Market.
    • Argo Blockchain plc (NASDAQ:ARBK) shares fell 38.1% to $0.4246. Argo Blockchain recently announced a November operational update..
    • Avaya Holdings Corp. (NYSE:AVYA) dropped 38% to $0.7149. Avaya disclosed certain information related to ongoing constructive discussions with financial stakeholders.
    • Midatech Pharma plc (NASDAQ:MTP) fell 30% to $1.17. Midatech Pharma PLC proposed acquisition of Bioasis Technologies Inc.
    • China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) shares dipped 29% to $5.05 after gaining around 115% on Monday.
    • Getaround, Inc. (NYSE:GETR) fell 28.8% to $1.46 after dropping 32% on Monday. Getaround recently announced closing of business combination with InterPrivate II Acquisition Corp.
    • Edible Garden AG Incorporated (NASDAQ:EDBL) fell 24.4% to $0.3225 after jumping over 59% on Monday.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) dropped 24% to $0.1521. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
    • Aptevo Therapeutics Inc. (NASDAQ:APVO) fell 23.2% to $3.00. Aptevo Therapeutics shares surged 14% on Monday after the company announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve AML patients.
    • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) dropped 23% to $8.31.
    • Hyperfine, Inc. (NASDAQ:HYPR) shares fell 21.9% to $0.9601. Hyperfine, on December 6, committed to organizational restructuring designed to decrease costs, create streamlined organization to support business, and has terminated approximately 13% of its global workforce.
    • Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) dropped 20% to $0.80.
    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) dipped 20% to $1.1250. Harpoon Therapeutics recently announced it presented updated interim results at ASH 2022 for novel T cell engager HPN217 in relapsed/refractory multiple myeloma.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) declined 19.8% to $0.8180.
    • Enzo Biochem, Inc. (NYSE:ENZ) fell 19.4% to $1.49 following Q1 results.
    • Ambrx Biopharma Inc. (NYSE:AMAM) shares fell 19.2% to $2.3099 after dipping 37% on Monday.
    • Adamas One Corp. (NASDAQ:JEWL) shares fell 17.3% to $3.9250.
    • Curis, Inc. (NASDAQ:CRIS) fell 17% to $0.5399. Curis shares announced additional clinical data from the TakeAim Leukemia study of emavusertib.
    • Bone Biologics Corporation (NASDAQ:BBLG) dropped 16.8% to $0.2446.
    • SeqLL Inc. (NASDAQ:SQL) fell 16.2% to $0.44.
    • The Lion Electric Company (NYSE:LEV) fell 14.5% to $2.2810. Lion Electric reported pricing of 19,685,040 unit offering at $2.54 per unit.
    • Aerovate Therapeutics, Inc. (NASDAQ:AVTE) fell 11.5% to $27.00. Aerovate Therapeutics, last month, posted a Q3 loss of $0.56 per share.
    • Nikola Corporation (NASDAQ:NKLA) fell 11.5% to $2.0699.
    • Silvergate Capital Corporation (NYSE:SI) dropped 11.5% to $18.80. JP Morgan maintained Silvergate Capital with an Overweight and lowered the price target from $50 to $30.
    • Engine Gaming and Media, Inc. (NASDAQ:GAME) fell 9.3% to $0.9584 after jumping 95% on Monday. The company last Thursday announced it has entered into an agreement to combine with GameSquare Esports.
    • JetBlue Airways Corporation (NASDAQ:JBLU) fell 8.6% to $7.03 as the company said it expects Q4 revenue per ASM at the low end of its guidance range.

    Also check this out Ethereum Jumps Above This Major Level; Toncoin Emerges As Top Gainer.

    Get the next $ACMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACMR
    $AMAM
    $ANGI
    $APVO

    CompanyDatePrice TargetRatingAnalyst
    Phathom Pharmaceuticals Inc.
    $PHAT
    3/27/2026$18.00Equal Weight → Overweight
    Barclays
    Oracle Corporation
    $ORCL
    3/24/2026$200.00Buy
    BofA Securities
    JetBlue Airways Corporation
    $JBLU
    3/24/2026$4.50Market Perform
    BMO Capital Markets
    Fluence Energy Inc.
    $FLNC
    3/20/2026Hold
    Needham
    Fluence Energy Inc.
    $FLNC
    3/19/2026Sell → Neutral
    Guggenheim
    Prenetics Global Limited
    $PRE
    3/16/2026$29.00Buy
    Lake Street
    Summit Therapeutics Inc.
    $SMMT
    3/16/2026$15.00Buy → Hold
    Jefferies
    Oracle Corporation
    $ORCL
    3/11/2026$210.00Neutral → Overweight
    Analyst
    More analyst ratings

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phathom Pharmaceuticals upgraded by Barclays with a new price target

    Barclays upgraded Phathom Pharmaceuticals from Equal Weight to Overweight and set a new price target of $18.00

    3/27/26 8:43:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on Oracle with a new price target

    BofA Securities resumed coverage of Oracle with a rating of Buy and set a new price target of $200.00

    3/24/26 8:49:56 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    BMO Capital Markets initiated coverage on JetBlue Airways with a new price target

    BMO Capital Markets initiated coverage of JetBlue Airways with a rating of Market Perform and set a new price target of $4.50

    3/24/26 8:40:25 AM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MediaCo's HOT 97 TV Channel to Launch March 31st in New York on WASA OTA and Spectrum

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced the expansion of HOT 97 TV in its home market, launching over-the-air on WASA-TV on March 31st. WASA-TV will also continue to be available on Spectrum channels 811 and 1236 across the New York metro area. Born in New York and built into one of the most influential brands in hip hop, HOT 97 has defined culture for decades with breaking artists, shaping conversations, and setting the soundtrack for the city. Now, that legacy continues to expand across television, streaming, and digital platforms. HOT 97 TV brings the brand's most iconic voices and franchises to screen, including: Mornings with Mero - brings unmatched credibility, humor

    3/30/26 9:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

    FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California. Presentation Details: Title: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint InhibitorPresenter / Authors: Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang,

    3/30/26 7:30:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    How Decentralized AI is Unlocking Value in Cardiac Diagnostics

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

    3/27/26 9:30:00 AM ET
    $BEAT
    $GEHC
    $HTFL
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ra Capital Management, L.P.

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    3/30/26 8:30:55 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Carson Bailey

    4 - Angi Inc. (0001705110) (Issuer)

    3/30/26 7:45:49 PM ET
    $ANGI
    Advertising
    Consumer Discretionary

    SEC Form 4 filed by Hicks Bowman Angela R.

    4 - Angi Inc. (0001705110) (Issuer)

    3/30/26 7:41:56 PM ET
    $ANGI
    Advertising
    Consumer Discretionary

    $ACMR
    $AMAM
    $ANGI
    $APVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Wave Life Sciences Ltd.

    SCHEDULE 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    3/30/26 8:32:33 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edible Garden AG Incorporated filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Edible Garden AG Inc (0001809750) (Filer)

    3/30/26 5:32:27 PM ET
    $EDBL
    Farming/Seeds/Milling
    Consumer Staples

    ClearSign Technologies Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ClearSign Technologies Corp (0001434524) (Filer)

    3/30/26 5:29:46 PM ET
    $CLIR
    Industrial Machinery/Components
    Industrials

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Leadership Updates

    Live Leadership Updates

    View All

    Oracle Scales Up Nashville Offices to Support Rapid Growth

    New lease at the Neuhoff Development adds over 116,000 square feet to Oracle's Nashville footprintAUSTIN, Texas, March 26, 2026 /PRNewswire/ -- To accommodate future growth of its Nashville workforce, Oracle has signed a new 116,000 square foot lease within The Neuhoff District, at 1320 Adams Street. With this latest investment, Oracle will bring its office capacity in Nashville to about 2,000 seats across three locations, marking significant progress in the company's plans to create thousands of new tech jobs and become a cornerstone of the local economy. "New candidates as wel

    3/26/26 6:49:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    MediaCo Appoints Armando Diaz as Vice President, Operations & Efficiency

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced the appointment of Armando Diaz as Vice President, Operations & Efficiency. Diaz will report to Brian Fisher, Chief Revenue Officer of MediaCo. In this role, Diaz will focus on strengthening operational discipline across the organization, simplifying internal processes, and driving sustainable expansion in support of the company's EBITDA growth strategy. Diaz brings more than 20 years of corporate leadership experience, including senior roles within media and broadcast organizations where he has led complex operational environments and cross-functional teams. Throughout his career, he has driven efficiency and transformation initiatives

    3/16/26 8:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    MediaCo Appoints Neida Gotay as Vice President, Integrated Sales

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced the appointment of Neida Gotay as Vice President, Integrated Sales. In this role, Gotay will oversee both local and national sales operations in Orlando and Atlanta, while also leading strategic business development efforts across all Florida markets. She will focus on driving integrated, multi-platform revenue growth, strengthening agency and client partnerships, and ensuring local market execution aligns with MediaCo's expanding national opportunity. Gotay brings deep experience in media sales leadership and revenue strategy, including 18 years at Hearst Television where she played a key role in building and expanding its network of S

    3/13/26 9:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

    At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization of lean mass (+2%), and reductions in waist circumference (-3%) and body weight (-1%) WVE-007 led to greater improvement in body composition (visceral fat-to-muscle ratio) at six months versus that seen with weekly GLP-1 in later-stage trial (BMI: ~37 kg/m2), even with participants in Phase 1 portion of INLIGHT™ having substantially lower BMI (~32 kg/m2) and lower levels of fat than those in Phase 2 and 3 obesity studies Phase 2a portion of INLIGHT in individuals with higher BMI (35-50 kg/m2)

    3/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Reports 2025 Year-End Financial Results

    Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors progressed after first line therapy — DUBLIN-3 study results published in The Lancet Respiratory Medicine Confirmatory Trial Planned: Based on DUBLIN-3 Phase 3 data and US FDA discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient population progressed on immune checkpoint inhibitors (NCT07361484)Overcoming Immunotherapy Resistance: Early clinical data at MD A

    3/25/26 8:30:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edible Garden Schedules Fourth Quarter and Full Year Ended December 31, 2025, Financial Results and Business Update Conference Call

    BELVIDERE, NJ, March 24, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:EDBL, EDBLW)), a leader in controlled environment agriculture (CEA), locally grown, organic, better-for-you, sustainable produce and products, announced today that it will host a conference call on Tuesday March 31, 2026, at 4:30 PM Eastern Time to discuss financial results for the quarter and year ended December 31, 2025, and provide a business update. The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 722201. A webcast of the call may be acces

    3/24/26 9:05:00 AM ET
    $EDBL
    Farming/Seeds/Milling
    Consumer Staples

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pinterest Inc.

    SC 13G/A - PINTEREST, INC. (0001506293) (Subject)

    12/6/24 10:11:26 AM ET
    $PINS
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Gaotu Techedu Inc.

    SC 13G/A - Gaotu Techedu Inc. (0001768259) (Subject)

    11/27/24 6:02:40 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care